Answers are grounded in this paper and cite their sources.
In the current issue of Clinical Infectious Diseases, Hjalmarsson et al. [1] report the incidence, mortality, and morbidity associated with herpes simplex encephalitis (HSE) in Sweden over a period of 11 years. Using the truly unique Swedish database, maintained by their national health care system for capturing targeted diseases, the authors confirmed 236 of 638 presumed cases of HSE, giving an incidence of 2.2 cases per 1 million population per year. In addition, another 11 cases were proven, but the virus was untyped (i.e., it was not determined whether infection was caused by herpes simplex virus type 1 [HSV-1] or type 2 [HSV-2]). Cases were confirmed by either PCR detection of viral DNA in the CSF or by intrathecal antibody synthesis. Of the patients with non–HSV-1 cases, 75 had evidence of HSV-2–related meningitis, and the remainder either did not have a positive diagnostic test result or did not have appropriate studies performed. Of interest, many of these patients subsequently received an alternative diagnosis, including brain tumor and stroke, among others. This recognition further underscores the difficulty of making a clinical diagnosis of HSE predicated upon presenting signs and symptoms. In summarizing their clinical data, Hjalmarsson et al. [1] report an overall mortality of 14%, increasing to 25.4% by the end of the first year after treatment. Patients, on average, were followed up for a median of 4.3 years. Rehospitalization was frequent (occurring in 87% of patients) and most often occurred for a seizure disorder, other infection, neuropsychiatric illness, or thromboembolic phenomena. Indeed, during the first year after diagnosis, the patients were hospitalized for a median of 55 days and required a median of 4 hospitalizations of 6 days' duration each. The current analysis [1] reinforces many fundamental tenets of our knowledge of HSE and further defines the incidence of HSE in the most accurate fashion to date. First, the long-term mortality of 26% and the substantial morbidity associated with HSE are significant. Despite the first report of successful antiviral therapy of HSV infection of the brain [2] with vidarabine and subsequent reports of the benefit of acyclovir [3, 4], the long-term outcome remains unsatisfactory. The data presented from the Swedish study [1] emphasize both the significant medical and financial burdens that HSE places on the health care delivery system. In the current era of noninvasive diagnosis, use of PCR to confirm the diagnosis of HSE, and early initiation of acyclovir therapy in many emergency departments, outcomes may well be improved, compared with those in historical reports. Toward this end, a collaborative study involving Swedish, Canadian, British, and American investigators (the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group) will define the potential benefit of long-term antiviral therapy, predicated on the hypothesis that ongoing viral replication may contribute to disease-associated morbidity. Whether a short course of corticosteroid therapy, as evaluated in animal models [5], or combination antiviral therapies would further improve outcomes remains to be proven in human clinical trials. Second, as the authors appropriately note, the diagnosis of HSE has moved well beyond the detection of HSV antibodies in the CSF and now relies almost totally on PCR detection of viral DNA. However, there is great heterogeneity in the quality control used by many laboratories in the United States that perform PCR assays. For the detection of HSV DNA, PCR tests remain “home brews,” with considerable variability from one laboratory to another. Although not a component of the current article, the application of PCR data to patient management warrants a note of caution. As with any other laboratory test, a false-negative PCR result can occur. Negative CSF PCR results have occasionally been noted very early in the course of HSV encephalitis. Therefore, it is prudent for physicians to continue acyclovir therapy for patients with altered mentation, encephalitis, and focal neurologic findings for whom no alternative diagnosis is apparent, until an additional PCR result can be obtained. Finally, as we have already alluded, further improvements in drugs to treat HSV infection of the CNS are indicated, whether the syndrome is HSE or neonatal HSV infection of the brain. Acyclovir is the mainstay of current treatment regimens, but the drug does not penetrate the CNS to a significant extent because of the lack of lipophilicity. The outcomes associated with HSV infection of the CNS would strongly suggest the need for improved drugs; however, there is little incentive for the pharmaceutical industry to take on this challenge, because there is a lack of financial remuneration associated with developing drugs to treat these relatively uncommon but frequently lethal diseases. Potential conflicts of interest. R.J.W and J.W.G.: no conflicts.
No takes yet. Share an insight, caveat, or question.
Whitley et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: